<DOC>
	<DOC>NCT00104143</DOC>
	<brief_summary>This study will compare the effect of A4I antagonist and placebo on MRI lesions,on clinical endpoints, and safety in patients with relapsing Multiple Sclerosis (MS). Eligible patients will be randomized to receive placebo or A4I antagonist, 20mg, 80mg or 300mg, po bid. Patients will undergo MRI brain scans and MS clinical evaluations at intervals throughout the study. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>adult patients, 1859 years of age; relapsing multiple sclerosis patients with types 14 (established through McDonald criteria); &gt;=1 MS attack or a Gdenhancing MRI lesion between 1 month and 1 year before enrollment; EDSS score of &lt;=6.5; inadequate response to approved treatment(Canada only). MS attack within 1 month before enrollment; systemic corticosteroids within 1 month before enrollment; MS treatments (nonsymptomatic) within specified periods before enrollment; an infection requiring systemic antiinfective treatment or vaccination with a live vaccine within 1 month before enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>